LEXINGTON, Mass., March 08, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today announced that a scientific poster and presentation describing its proprietary product platform and the identification of its lead product candidate, KB195, will be featured during the Keystone Symposia meeting, Microbiome: Chemical Mechanisms and Biological Consequences, which will be held from March 10-14, 2019, in Montreal, Québec.
The poster entitled, “Developing a Drug Discovery Platform to Target Gut Microbiota-Associated Ammonia Production,” will be displayed during Poster Session 2 from 7:30-10:00 pm ET on Tuesday, March 12, 2019. Christopher Liu, Ph.D., Kaleido’s Head of Chemistry, will also present the findings during the Roles of Pharmaceutical Industry in Microbiome Research workshop, scheduled from 3:00-4:30 pm ET on Wednesday, March 13, 2019. Kaleido intends to make the poster available on the Platform page of its website, https://kaleido.com/ following the poster session.
Kaleido has built a human-centric proprietary product platform to discover and develop novel Microbiome Metabolic Therapies (MMT™) designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the organ’s existing microbes. The poster that will be presented describes the identification of MMTs with the potential to reduce net ammonia production by the gut microbiome and demonstrate improved tolerability over clinical standards of care. Ex vivo screening of microbiome samples from healthy volunteers followed by ex vivo testing of microbiome samples from patients with urea cycle disorders (UCD) and patients with hepatic impairment was effective in identifying KB195 for further development. KB195 was subsequently evaluated in a randomized, double-blind, placebo-controlled, non-Investigational New Drug (non-IND) clinical study in healthy human subjects, and was observed to have a significant reduction in ammonia compared to placebo (as measured by urinary 15N excretion) and to have favorable tolerability.
Kaleido has received IND clearance from the U.S. Food and Drug Administration for a Phase 2 clinical trial evaluating KB195 as a potential treatment for hyperammonemia in patients with UCD, and expects to initiate enrollment during the first half of 2019. The Company is also conducting a non-IND clinical study in patients with UCD and anticipates the results of this study in the fourth quarter of 2019.
About Kaleido Biosciences
Kaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health. The Company has built a human-centric proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies (MMT™). MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the organ’s existing microbes. Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs. To learn more, visit https://kaleido.com/.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the anticipated use of our existing cash resources, including proceeds from our initial public offering, the duration for which our existing capital resources will fund our operations statements regarding the therapeutic potential of our MMT candidates and our strategy, business plans and focus. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those related to the planned Phase 2 clinical trial for KB195 for the treatment of UCD, the clinical development and safety profile of our MMT candidates and their therapeutic potential, whether and when, if at all, our MMT candidates will receive approval form the U.S. Food and Drug Administration and for which, if any, indications, competition from other biotechnology companies, and other risks identified in our SEC filings, including our final prospectus for our initial public offering, and subsequent filings with the SEC. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent our views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements.
Contact
Kaleido Biosciences
Amy Reilly
617-890-5721
amy.reilly@kaleido.com